- Home
- VPG vs MNPR Comparison
VPG vs MNPR Comparison
Compare VPG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VPG
- MNPR
- Stock Information
- Founded
- VPG 2009
- MNPR 2014
- Country
- VPG United States
- MNPR United States
- Employees
- VPG N/A
- MNPR N/A
- Industry
- VPG Electrical Products
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- VPG Technology
- MNPR Health Care
- Exchange
- VPG Nasdaq
- MNPR Nasdaq
- Market Cap
- VPG 427.5M
- MNPR 390.5M
- IPO Year
- VPG N/A
- MNPR 2019
- Fundamental
- Price
- VPG $37.46
- MNPR $86.16
- Analyst Decision
- VPG
- MNPR Strong Buy
- Analyst Count
- VPG 0
- MNPR 12
- Target Price
- VPG N/A
- MNPR $96.64
- AVG Volume (30 Days)
- VPG 141.2K
- MNPR 97.3K
- Earning Date
- VPG 11-04-2025
- MNPR 11-10-2025
- Dividend Yield
- VPG N/A
- MNPR N/A
- EPS Growth
- VPG N/A
- MNPR N/A
- EPS
- VPG N/A
- MNPR N/A
- Revenue
- VPG $295,282,000.00
- MNPR N/A
- Revenue This Year
- VPG N/A
- MNPR N/A
- Revenue Next Year
- VPG $5.40
- MNPR N/A
- P/E Ratio
- VPG N/A
- MNPR N/A
- Revenue Growth
- VPG N/A
- MNPR N/A
- 52 Week Low
- VPG $18.57
- MNPR $12.55
- 52 Week High
- VPG $38.90
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- VPG 60.16
- MNPR 57.75
- Support Level
- VPG $35.51
- MNPR $77.00
- Resistance Level
- VPG $38.90
- MNPR $89.32
- Average True Range (ATR)
- VPG 1.99
- MNPR 7.00
- MACD
- VPG 0.14
- MNPR -1.45
- Stochastic Oscillator
- VPG 78.60
- MNPR 44.25
About VPG Vishay Precision Group Inc.
Vishay Precision Group Inc manufactures and markets sensors, and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.